Posts by Sandra Ansanay-Alex
Lonza invested CHF 1 billion in Visp in 2022
The biopharmaceutical company employs 5,000 people in Valais, and also announced a 15% sales growth in 2022, representing a total of CHF 6.2 billion Lonza has invested one billion francs in Visp (VS) and half a billion in Stein (AG) in 2022, according to the chairman of the group’s board of directors, Albert Baehni. Some…
Read MoreCHUV, Alithea Genomics and PanGene partner to develop a pan-cancer blood test
The three partners secured a €1 million ($1.1 million) in Eurostars grant funding to develop a first of a king pan-cancer blood test to guide immune checkpoint inhibitor (ICI) therapy. The consortium combines an expertise in clinical research, transcriptomics and kinomic profiling to take a radically new approach to identify a multi-omics biomarker profile…
Read MoreBioAlps and the Swiss Health Valley
Listen to Magali Bischof, BioAlps Secretary General, on Beyond Biotech podcast speaking about the Swiss Health Valley and the role of BioAlps association. Here is the transcription of the interview. ▶️ Listen to the podcast on Labiotech.eu | From 00:31:50 to 47:30 Could you tell us about BioAlps – when it was formed,…
Read MoreCHUV, EPFL, SIB and Roche found molecules able to suppress resistance to immunotherapy
A breakthrough in the fight against cancer: researchers from EPFL, the Ludwig Institute of the CHUV, the SIB, and Roche have discovered have successfully tested on mice a combined treatment that attacks the most resistant tumors. A test on humans will follow. Immunotherapy is a cancer treatment that involves reprogramming a patient’s immune system…
Read MoreModerna plans to produce a RNA vaccine against RSV in Valais
Moderna, which developed one of the first messenger RNA vaccines against Covid-19, has disclosed positive preliminary results for a trial against the Respiratory Syncytial Virus (RSV), which causes bronchiolitis, in the elderly. The vaccine will be produced in Boston (USA) and in Visp (Switzerland) The phase 3 trial is being conducted in a double-blind…
Read MoreThe HUG open a Centre for Virtual Medicine
The new Centre for Virtual Medicine at the HUG is a pioneer in the use of virtual reality for clinical research and medical practice. The Centre for Virtual Medicine (CMV) is the result of collaboration between the Departments of Diagnostics, Clinical Neurosciences and Medicine and the Swiss Federal Institute of Technology in Lausanne (EPFL).…
Read MoreBIONOMOUS closes a USD 2.7 million Series A
The Swiss-based startup builds devices to automate processes in Life Science research and prepares a product rollout and expansion. The round was led by Nivalis Group, a Swiss Holding based in Villaz-St-Pierre, with participation from Cybernetix Ventures, a leading robotics-focused US venture capital firm based in the Boston, and Capital Risque Fribourg, an early-stage…
Read MoremAm | Micronarc Alpine Meeting
The next edition of Micronarc Alpine Meeting is taking place on 20-21 April 2026 at Villars-sur-Ollon. Following in the success of its previous editions, the Micronarc Alpine Meeting, mAm, will continue its focus on equipment and innovative processes and technologies for manufacturing microproducts. This 2 day conference is a proven venue for stimulating quality…
Read MoreVirtual reality glasses used as a diagnostic tool for brain disorders
MachineMD, a spin-off of Inselspital Bern, and CSEM, are collaborating to diagnose brain diseases by analyzing eye movements with a virtual reality headset. Their tool, neos, has been awarded the first prize by the Ypsomed Innovation Fund. machineMD is an exemplary product of the well-connected Bernese startup ecosystem. Prof Dr Mathias Abegg has been…
Read MoreNeurosoft Bioelectronics receives ISO Certification for its Quality Management System
Neurosoft Bioelectronics SA, a startup developing implantable brain-computer interfaces, announces that it has received ISO 13485:2016 Certification by TÜV SÜD for its Quality Management System. This is a major milestone for Neurosoft Bioelectronics as it brings the company one step closer to its first clinical studies and regulatory approval of their first product :…
Read More